



India Emerges as an Important Destination for Global Pharmaceutical CompaniesPosted AtStreetinsider.comDUBLIN, Ireland--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/reports/c90183) has announced the addition of India: Pharmaceutical to their offering. In 2006, India ranked 12th in the global pharmaceutical market in dollar terms with a market share of 1.27% globally. It was estimated that India's pharmaceutical industry was worth USD 8.8 billion in 2005. Indian companies continue to dominate the generic market with a total market share of 70% in 2006. Meanwhile, India's pharmaceutical industry accounted for approximately 21% of the global DMFs. India has 75 US FDA approved plants, the highest number of US FDA approved plants outside US. Apart from the relatively low development cost and skilled manpower, the availability of raw materials at competitive prices makes India a preferred manufacturing hub for pharmaceutical giants. Another obvious reason is its IT prowess. As pharmacy research becoming more and more IT oriented, India is in a position to leverage on its strong IT base. India is also emerging as an important destination for global pharmaceutical companies, which are increasingly considering outsourcing and off shoring their drug discovery, research and development, and clinical research. Contents: 1. Industry Profile 1.1 Sector Overview 1.2 Sector Size and Value 1.2.1 Generic Market 1.2.2 Drug Master File (DMF) Filings 1.2.3 US FDA Approved Manufacturing Plants 1.3 Sector Performance 1.3.1 Pharmaceutical Production 1.3.2 Pharmaceutical Export 2. Market Trends and Outlook 2.1 New Patent Law 2.2 Regulatory Changes 2.3 R&D Spending 2.4 Exploiting Generic Opportunities 2.5 Contract Research and Manufacturing (CRAM) 3. Leading Players and Comparative Matrix 3.1 Leading Players 3.1.1 Dr. Reddy's Laboratories 3.1.2 Ranbaxy Laboratories 3.1.3 Cipla 3.1.4 Sun Pharmaceutical 3.1.5 Wockhardt 3.2 Comparative Matrix 3.3 SWOT Analysis Companies Mentioned: - Dr. Reddy's Laboratories - Ranbaxy Laboratories - Cipla - Sun Pharmaceutical - Wockhardt For more information visit http://www.researchandmarkets.com/reports/c90183 Source: Research and Markets April 28, 2008
|